Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtDvance long-term extension of GSK1070806 in atopic dermatitis
jRCT2031240179Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of aletekitug in atopic dermatitis (AD), sponsored by GSK. Primary endpoints: Number of participants with adverse events (AEs), Number of participants with AEs leading to discontinuation of GSK1070806 and 2 more. Started Jul 2024; status: completed.
02
Drugs
aletekitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031240179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240179.